DUBLIN, Ireland & AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) and its subsidiary, Gendux Molecular Limited (“GML”), today announced that a Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMEA) for ADVEXIN®, a targeted p53 tumor suppressor therapy for the treatment of Li-Fraumeni Syndrome cancers (LFS).
